search icon
      blog search icon

      Enochian Biosciences, Inc. (ENOB) stock is declining in aftermarket – Here’s why? - Stocks Telegraph

      By Mahrukh Rehan

      Published on

      November 22, 2021

      7:06 AM UTC

      Enochian Biosciences, Inc. (ENOB) stock is declining in aftermarket – Here’s why? - Stocks Telegraph

      Enochian Biosciences, Inc. (ENOB) experienced a decline of 6.41% in the aftermarket. However, the last trading session closed at $11.07 with an increase of 10.04%.

      Successful Completion of an FDA Pre-IND – What’s it about?

      ENOB successfully announced on 18th October 2021 that the Investigator Pre-Investigational New Drug (IND) process has been completed. Dr. Serhat Gumrukçu, co-founder and creator of Enochian BioSciences and Director of Seraph Research Institute (SRI) initiated an investigator-initiated Pre-IND.

      Moreover, the request was based on the findings of a 54-year-old HIV-positive male who had not been able to suppress the virus with antiviral medication (ART). Following that, the patient stopped using ART and received an SRI-developed therapy. However, Enochian BioSciences licensed the product. Last but not least, the patient’s HIV infection blood levels were managed more successfully for 365 consecutive days off ART utilizing this novel revolutionary SRI medication.

      What does ENOB say about it?

      ENOB appreciates the FDA’s thoughtful and helpful remarks, which have now cleared the way for them to file an IND in the near future. Also, the company is happy to know that they are one step closer to making this medicine available to more individuals living with HIV.

      Despite the fact that the results are preliminary and only in one individual, the sooner the strategy can be tested in others, the better. If confirmed to be successful, it might provide hope to many people who are looking for alternatives to expensive and difficult-to-maintain daily treatments.

      Resignation of Scientific Advisory Board Member – But why?

      On 15th October 2021, ENOB announced that Dr. Peter Piot, the Chairperson of the Respiratory Diseases Scientific Advisory Board, has resigned due to major obligations instructing a major governmental organization on COVID-19 which created a conflict.

      However, Dr. Peter says that the groundbreaking science and promise of Enochian BioSciences’ whole pipeline continues to impress and excite him. But his obligations as a consultant to a government agency prevent him, from continuing as a scientific advisor.

      New Joining to ENOB – Who are they?

      ENOB announced the appointment of Dr. Peter and Dr. Richard on 30th August 2021. Dr. Peter has worked on pandemics for over 40 years. Not only this, but he is well aware of the complexity of the scientific approach to possibly cure and prevent any forms of SARS-CoV-2 and Influenza. Perhaps more importantly, Enochian’s products may be able to avert future corona- and influenza-virus pandemics.

      On the other hand, Dr. Richard is looking forward to working with ENOB as they strive to create medicines. That might be critical in controlling and, eventually, ending the COVID-19 epidemic. This might potentially restrict disease while also spreading the virus, making it a win-win situation.

      More From Stocks telegraph